Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana T Nunes

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Seminars in Oncology|June 25, 2018
Proteasome inhibitors: structure and functionAna T Nunes, Christina M Annunziata
Gynecologic Oncology Reports|December 24, 2019
Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?Bradley J Monk, Jyoti Mayadev, Ana T Nunes
Cytokine & Growth Factor Reviews|March 31, 2016
Monocyte and interferon based therapy for the treatment of ovarian cancerDaniel S Green, Ana T Nunes, Christina M Annunziata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 25, 2020
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter studyJyoti Mayadev, Ana T Nunes, Mary Li, et al.
Journal of Translational Medicine|July 18, 2018
A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron<sup>®</sup> (Peginterferon alfa-2b) and Actimmune<sup>®</sup> (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancerDaniel S Green, Ana T Nunes, Virginia David-Ocampo, et al.
Journal of Translational Medicine|March 16, 2019
Production of a cellular product consisting of monocytes stimulated with Sylatron<sup>®</sup> (Peginterferon alfa-2b) and Actimmune<sup>®</sup> (Interferon gamma-1b) for human useDaniel S Green, Ana T Nunes, Kevin W Tosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2022
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Seminars in Oncology|June 25, 2018
Proteasome inhibitors: structure and functionAna T Nunes, Christina M Annunziata
Gynecologic Oncology Reports|December 24, 2019
Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?Bradley J Monk, Jyoti Mayadev, Ana T Nunes
Cytokine & Growth Factor Reviews|March 31, 2016
Monocyte and interferon based therapy for the treatment of ovarian cancerDaniel S Green, Ana T Nunes, Christina M Annunziata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 25, 2020
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter studyJyoti Mayadev, Ana T Nunes, Mary Li, et al.
Journal of Translational Medicine|July 18, 2018
A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron<sup>®</sup> (Peginterferon alfa-2b) and Actimmune<sup>®</sup> (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancerDaniel S Green, Ana T Nunes, Virginia David-Ocampo, et al.
Journal of Translational Medicine|March 16, 2019
Production of a cellular product consisting of monocytes stimulated with Sylatron<sup>®</sup> (Peginterferon alfa-2b) and Actimmune<sup>®</sup> (Interferon gamma-1b) for human useDaniel S Green, Ana T Nunes, Kevin W Tosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2022
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical TrialDaniel S Green, Franklin Ning, Anna Duemler, et al.
Pageof 1